Krystal Biotech (NASDAQ:KRYS) Director Sells $4,953,719.50 in Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) Director Dino Rossi sold 18,950 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $261.41, for a total transaction of $4,953,719.50. Following the completion of the transaction, the director directly owned 78,691 shares of the company’s stock, valued at $20,570,614.31. This trade represents a 19.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Krystal Biotech Stock Performance

NASDAQ KRYS traded up $12.79 during trading on Monday, reaching $274.59. 294,320 shares of the company traded hands, compared to its average volume of 291,786. Krystal Biotech, Inc. has a 1-year low of $122.80 and a 1-year high of $298.30. The company has a market cap of $8.03 billion, a price-to-earnings ratio of 40.09 and a beta of 0.49. The stock’s 50 day moving average price is $266.13 and its two-hundred day moving average price is $211.66.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Tuesday, February 17th. The company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%.The company had revenue of $107.11 million during the quarter, compared to analysts’ expectations of $105.30 million. Equities research analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on KRYS shares. HC Wainwright reiterated a “buy” rating and issued a $310.00 price objective (up from $240.00) on shares of Krystal Biotech in a research report on Friday, January 9th. Bank of America upped their price target on Krystal Biotech from $288.00 to $318.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Weiss Ratings upgraded Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, February 18th. TD Cowen reissued a “buy” rating on shares of Krystal Biotech in a report on Friday, January 9th. Finally, The Goldman Sachs Group raised their target price on shares of Krystal Biotech from $206.00 to $327.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, Krystal Biotech currently has a consensus rating of “Moderate Buy” and a consensus target price of $318.75.

Hedge Funds Weigh In On Krystal Biotech

Hedge funds have recently added to or reduced their stakes in the stock. EFG Asset Management North America Corp. raised its position in shares of Krystal Biotech by 18.4% in the 3rd quarter. EFG Asset Management North America Corp. now owns 27,095 shares of the company’s stock worth $4,784,000 after acquiring an additional 4,217 shares in the last quarter. Edgestream Partners L.P. bought a new stake in Krystal Biotech during the 2nd quarter worth approximately $2,705,000. Voya Investment Management LLC lifted its holdings in shares of Krystal Biotech by 46.7% in the third quarter. Voya Investment Management LLC now owns 93,908 shares of the company’s stock valued at $16,578,000 after purchasing an additional 29,915 shares in the last quarter. State of New Jersey Common Pension Fund D grew its position in Krystal Biotech by 45.2% in the 2nd quarter. State of New Jersey Common Pension Fund D now owns 15,033 shares of the company’s stock worth $2,066,000 after purchasing an additional 4,682 shares in the last quarter. Finally, Norges Bank bought a new stake in Krystal Biotech during the second quarter worth $38,861,000. Institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.